Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Reeves

Showing results (471-480 of 491) with videos related to

Pageof 50
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2010
SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesisRuth Luthi-Carter, David M Taylor, Judit Pallos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2017
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaJohn P Leonard, Kathryn S Kolibaba, James A Reeves, et al.
Clinical Genitourinary Cancer|July 10, 2020
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 StudyJoshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, et al.
Journal of the National Cancer Institute|December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyBrian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
NPJ Precision Oncology|July 26, 2019
Blood-based monitoring identifies acquired and targetable driver <i>HER2</i> mutations in endocrine-resistant metastatic breast cancerArielle J Medford, Taronish D Dubash, Dejan Juric, et al.
Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.
Breast Cancer Research and Treatment|June 15, 2023
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cellsTaronish D Dubash, Aditya Bardia, Brian Chirn, et al.
Science Advances|November 29, 2023
GDF8 inhibition enhances musculoskeletal recovery and mitigates posttraumatic osteoarthritis following joint injuryCamille R Brightwell, Christine M Latham, Alexander R Keeble, et al.
Cell|June 16, 2023
DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCsHongshan Guo, Joanna A Vuille, Ben S Wittner, et al.
The Lancet. Oncology|March 1, 2023
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshopLalitha K Shankar, Heiko Schöder, Elad Sharon, et al.
Pageof 50

Showing results (471-480 of 491) with videos related to

Sort By:
Pageof 50
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2010
SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesisRuth Luthi-Carter, David M Taylor, Judit Pallos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2017
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaJohn P Leonard, Kathryn S Kolibaba, James A Reeves, et al.
Clinical Genitourinary Cancer|July 10, 2020
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 StudyJoshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, et al.
Journal of the National Cancer Institute|December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyBrian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
NPJ Precision Oncology|July 26, 2019
Blood-based monitoring identifies acquired and targetable driver <i>HER2</i> mutations in endocrine-resistant metastatic breast cancerArielle J Medford, Taronish D Dubash, Dejan Juric, et al.
Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.
Breast Cancer Research and Treatment|June 15, 2023
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cellsTaronish D Dubash, Aditya Bardia, Brian Chirn, et al.
Science Advances|November 29, 2023
GDF8 inhibition enhances musculoskeletal recovery and mitigates posttraumatic osteoarthritis following joint injuryCamille R Brightwell, Christine M Latham, Alexander R Keeble, et al.
Cell|June 16, 2023
DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCsHongshan Guo, Joanna A Vuille, Ben S Wittner, et al.
The Lancet. Oncology|March 1, 2023
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshopLalitha K Shankar, Heiko Schöder, Elad Sharon, et al.
Pageof 50